CStone Launches Patient Assistance Program for IDH1 Inhibitor Tibsovo
CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support...
Cancer
HutchMed Announces Initial Results from FRUTIGA Phase III Study
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...
Daxiang Biotech Raises RMB 100M in Pre-Series B Financing for Organoid-on-a-Chip
Beijing-based Daxiang Biotech Co., Ltd., a leading domestic company in the organoid-on-a-chip field, has reportedly...
Henlius Biotech’s BRAF V600E Inhibitor HLX208 Approved for Clinical Study in China
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Peking University Study Identifies Liver Cancer Immune Microenvironment Subtypes
Researchers at Peking University have uncovered several subtypes in the tumor immune microenvironment (TIME) relevant...
Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...
Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE
Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...
Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500
China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...